PARK2 Antibody

Blue Ice

Predicted: 51 kDa
Observed: 55 kDa

Parkinson's disease (PD) is a neurodegenerative disease whose symptoms include tremors, rigidity, bradykinesia, and postural instability (1). Mutations in the PARK2 gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease (2). The PARK2 protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation (3). Recent studies have suggested that PARK2 expression reduces the mitochondrial accumulation of the apoptosis protein Bax under basal conditions and directly ubiquitinates Bax, thereby promoting cell survival (4).

Trial Size

169790969

PRS-1362-0.1mg

1 mg/mL

PARK2 antibody can be used for detection of PARK2 by Western blot at 1 - 2 μ g/ml. Antibody can also be used for Immunohistochemistry starting at 5 μ g/mL. For immunofluorescence start at 20 μ g/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

PARK2 antibody was raised against a 17 amino acid peptide near the amino terminus of human PARK2.

The immunogen is located within amino acids 110 - 160 of PARK2.

parkin RBR E3 ubiquitin protein ligase

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.